Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.

Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2018 May;16(5S):601-604 Authors: Reckamp KL Abstract Molecular testing is recommended for initial diagnosis in patients with non-small cell lung cancer (NSCLC), according to the updated NCCN Guidelines, because targeted therapies are available that can improve patient outcomes. Targeted therapies are currently approved for EGFR mutations, ALK and ROS1 gene rearrangements, and BRAF mutations, with the list of emerging "actionable" targets growing. The 2018 NCCN Guidelines for NSCLC incorporate new therapies, including the EGFR tyrosine kinase inhibitor osimertinib and the ALK inhibitor alectinib, as first-line preferences. PMID: 29784736 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research